More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Scientists found that obesity may exist in 11 biological forms, each linked to different genes and body functions.

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, ...

Findings reveal that the health of children in the U.S. has deteriorated across nearly every major health indicator over the ...

The MC4R agonist targets rare genetic and hypothalamic obesity, with potential as a combination or maintenance therapy for general obesity alongside GLP-1 agents.

Patients with idiopathic intracranial hypertension who use a GLP-1 receptor agonist are less likely to experience symptoms, require medications, or undergo surgery.

Clinical trial data review on weight-loss drugs reveals weight regain patterns post-medication discontinuation, impacting weight management strategies.

The prevalence of long COVID-typical symptom clusters was relatively high among a cohort of adults 2 years after initial COVID-19 infection.

Explore how semaglutide and tirzepatide may protect against dementia and stroke—keep reading for clinical implications and evidence.

Rajni Gupta, 56, underwent the procedure on July 11 but passed away on July 15 due to complications from the surgery that ...